Genentech oncology trend report. Discover the latest news...
Genentech oncology trend report. Discover the latest news about our company, our products, our policies, and our people. Trends in cancer care delivery – Oncology clinical pathways 2014 2016 Source: ASCO, The State of Cancer Care in America, 2017;The 2016 Genentech Oncology Trend Report: Perspectives from managed care, specialty pharmacies, oncologists, practice managers, and employers. 28 billion by 2034, at a CAGR of 12. S. Levi Garraway, Genentech CMO, discusses trends shaping the development of cancer medicines. About the authors 70 About the Institute 72 2 | Global O ncolog y Trends 2023: O utloo k to 2027 Global oncology R&D and innovation continue to expand, bringing forward new therapies for advanced About Genentech Founded nearly 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. 5 million in 2025 and anticipated to reach a value of USD 30,606. As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer care in 2025. Figure 2 (page 5) illustrates the flow of oncology patients through the financial navigation program and interactions between the financial navigation and treatment teams. , Bristol-Myers Squibb Company, GlaxoSmithKline plc. It's hard to know for certain what the landscape of oncology will look like years from now, but we can take a look at the top 7 trends in oncology pharmacy and care to see where we're headed. , Eli With one of the broadest oncology pipelines and portfolios in the industry, Genentech presentations include late-breaking abstracts featuring data in early-stage breast cancer and early-stage lung The information garnered from these interviews was qualitative in nature. The report explores the impact of COVID-19 disruptions and the longer-term trends in the use of cancer medicines as well as the drivers of spending globally, in key geographies, by tumor type, and for specific types of Up to 85 percent of people with cancer are treated in community practices by oncologists who treat a wide range of indications across different types of cancers. For each trend, it provides a “deep dive” into the companies and innovations that are driving it forward. Our power is in discovering innovative medicines and personalizing cancer care for all patients. Liver cancer is the sixth most common cause of cancer-related mortality in the United States and cases have tripled since 1980. Attention of community oncology practice leadership in 2021 has shifted somewhat from value-based reimbursement and adoption of biosimilars, as several trends/issues have emerged to disrupt the oncology segment. Key Takeaways | Oncology Perception Leader: Roche/Genentech emerges as the overall leader across geographies. Generic Oncology Drugs Market Outlook from 2025 to 2035 The global sales of generic oncology are estimated to be worth USD 23,743. In this report, we share our updated perspective on some of the trends we have observed in 2015, including new treatment options, availability of cancer treatments, costs of oncology therapeutics and supportive care drugs, distribution of cancer drugs, and some dynamics that are specific to the U. Mission Statement The mission of The 2013 Genentech Oncology Trend Report: Perspectives From Managed Care, Specialty Pharmacy Providers, Oncologists, Practice Managers, and Employers is to provide timely and useful information on the latest cancer care trends and developments. Biosimilar Q3 2025 ASP discounts as compared to the reference product’s ASP average -40%, -58%, and -67%, and -65% for the trastuzumab, bevacizumab, and rituximab markets, respectively. This report, which is packed with useful information, surveyed oncology practice managers working in three different settings: Community-based; Hospital-based; and Academic/Medical center-based. Here are five trends we at Genentech are particularly excited about. A separate quantitative analysis of trends in oncology managed care has already been published, and throughout this report, data from the 2009–2010 Genentech Oncology Trend Report are referenced to supplement findings from the NCCN interviews. q4default . The Global Oncology Trends 2025 report explores novel cancer therapies, rising expenditures, and access disparities. treated patient forecasts by tumor, country, target and The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting wasn’t just another scientific gathering—it was a seismic event that redrew the contours of modern cancer care. Global Oncology Trends 2025 Oncology rising costs, bispecific growth, infusion shift, and notable drug approvals This page highlights oncology therapeutic trends for spring 2025, including rising drug costs, increased use of bispecific agents, significant shifts in infusion site-of-care, biosimilar developments and impactful new and upcoming drug approvals. The chart below is derived from the 2016 Genentech Oncology Trend Report (free download). Pioneering together for a cancer-free tomorrow The new ZoomRx report analyzed more than 71,000 interactions with pharma sales reps reported by around 700 oncology healthcare professionals (HCPs) between July 2024 and June of this year. No single culprit is responsible for the climb in cancer costs according to a landmark Milliman study. A cancer-free tomorrow starts here. | As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. Prior to Aventria, David Guy held several commercial leadership roles, including Head of Oncology Marketing at Genentech and VP Strategic Marketing at Schering AG, specializing in commercializing oncology and specialty products. DATETITLE18 Apr 2024FDA Approves Genentech's Alecensa as . . We hoped industry layoffs would relent in 2024. Pioneering together for a cancer-free tomorrow. HIRC's report, Community Oncology Practices: Market Trends and Manufacturer Competitive Assessment, reviews oncology practices' strategic imperatives, quality of cancer care needs and Genentech Launches Oncology Clinical Trial Diversity Alliance Genentech Statement on FDA Oncologic Drug Advisory Meetings on April 27–29, 2021 Genentech and the Genentech Foundation Commit $42 Million to Address Immediate and Long-Term Effects of the COVID-19 Pandemic Genentech Congratulations 2019 Lasker Award Laureates Genentech Provides With one of the broadest oncology pipelines and portfolios in the industry, Genentech presentations include late-breaking abstracts featuring data in early-stage breast cancer and early-stage lung A growing government push for innovation has also fueled booming deal-making (about $30 billion in oncology licenses, mostly for ADCs and mAbs in 2024). , Novartis AG, Pfizer Inc. Oct 12, 2025 · The data underscore Genentech’s commitment to deliver transformative medicines for some of the most challenging cancer types, including breast cancers, lung cancers, gastrointestinal and genitourinary cancers. Despite the COVID-19 pandemic having a substantial impact on patient care during 2020, the scientific advances in clinical trial activity, the pipeline of new treatments, and the increased use of available therapeutics, continued largely unaffected and reflect the commitment to advancing care for patients by oncologists, other care providers, governments and payers, and life sciences companies. 2016. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. 6% over the forecast period between 2025 and 2035. The company, a member of the Roche Group, has headquarters in South San Francisco, California. Genentech Launches Oncology Clinical Trial Diversity Alliance Genentech Statement on FDA Oncologic Drug Advisory Meetings on April 27–29, 2021 Genentech and the Genentech Foundation Commit $42 Million to Address Immediate and Long-Term Effects of the COVID-19 Pandemic Genentech Congratulations 2019 Lasker Award Laureates Genentech Provides This oncology research from the IQVIA Institute profiles the current state of research and development in oncology, including key mechanisms, targets and cancer types being investigated as well as pointing to some novel areas which are only just emerging. Held in Chicago, the meeting spotlighted how the oncology landscape is shifting, rapidly and meaningfully, thanks to an unprecedented influx of data, innovation, and strategic alignment across pharma Across oncology biosimilars, WAC prices discounted between 10-40% compared to reference products. Each of the tools and resources listed here presents strategies for your consideration. bwalignc { text-align: center; list-style-position: inside } Step Will Advance Precision Oncology By Enabling Greater Efficiency in Clinical Decision Making Early disease detection, patient care coordination and patient-focused care management are important for achieving positive outcomes and patient satisfaction. Precision oncology market size was $115. A significant and accelerating trend in the global SERD drug market is the rapid advancement and clinical integration of next-generation oral SERDs, combined with precision oncology approaches targeting ESR1 mutations and endocrine-resistant breast cancer, significantly enhancing therapeutic effectiveness and patient convenience This year's Global Oncology Trend report examines those novel medicines and the clusters of research which promise a continuing sequence of breakthroughs in the decade to come. Hoffmann-La Roche Ltd, Genentech, Inc. 80 billion in 2024, is projected to reach $201. Read this case study about the Advancing Inclusive Research® Site Alliance, formed in part to help further participation in clinical trials amongst historically underrepresented patients. Up to 85 percent of people with cancer are treated in community practices by oncologists who treat a wide range of indications across different types of cancers. We are proud to have the broadest and most diverse pipeline in oncology, with more than 20 immunotherapy molecules currently in development. Key Companies Covered in the Oncology Drugs Market Research Report Are F. The global oncology drugs market size is projected to grow from $267. It highlights trends in ADCs, radioligand therapies, CAR-T, and spending projections through 2029. Since 2011, we have introduced 18 oncology medicines. Our Oncology Portfolio Find product and prescribing information, as well as other resources, for Genentech’s oncology portfolio below. Updated annually, the publication is designed to serve as a unique resource for those seeking an understanding of the Their Fight. Sales are projected to rise at a CAGR of 2. Learn more about membership here or login. IQVIA ONCOLOGY ANALYTICS PLATFORM is a ONCOLOGY LINK includes 10-year drug spending and syndicated platform specifically designed for the U. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. Our medicines, along with companion diagnostic tests, have contributed to bringing breakthrough outcomes in HER2-positive and triple-negative breast cancers. Trailblazing Trials After staying much the same for more than half a century, clinical trials are changing. The India Oncology Drug Discovery Market Trends India’s market is growing due to rising cancer incidence, increased healthcare spending, and expanding research infrastructure. Please see additional Important Safety Information in full Prescribing Information, including Patient Information. Global Oncology Trends 2021 Explore this Genentech report, which highlights key trends across the healthcare industry–from staffing, capacity, and burnout to digital health This paper identifies four trends that will define the oncology market’s evolution during 2025 and beyond. 05% from 2025 to 2030. That's not what happened. About Genentech in Breast Cancer Genentech has been advancing breast cancer research for more than 30 years with the goal of helping as many people with the disease as possible. A, 2020 Explore Genentech's innovative oncology pipeline 🎗️, focusing on cancer treatments, clinical trials, and groundbreaking therapies shaping future patient outcomes. The new ZoomRx report analyzed more than 71,000 interactions with pharma sales reps reported by around 700 oncology healthcare professionals (HCPs) between July 2024 and June of this year. 5 2019 Genentech Oncology Trend Report: Perspectives from managed care organizations, specialty pharmacies, oncologists, practice managers, and employers, Genentech U. 24 billion in 2026 to $667. . Our efforts are united by a commitment to exploring therapeutic combinations and pursuing personalized medicines. Follow along as BioSpace tracks job cuts and restructuring initiatives. From product information and patient access to screening initiatives, Genentech provides resources to help you and your patients, whether your focus is getting one patient on a Genentech therapy or on improving the entire patient population. About Genentech in lung cancer Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. A, 2020 In 2016, just a quarter of oncology practices considered themselves prepared for upcoming US Pharmacopeia (USP) standards on hazardous drug management, according to the 2017 Genentech Oncology The chart below is derived from the 2016 Genentech Oncology Trend Report (free download). Our Mission. Patients and caregivers may also report side effects to Genentech at (888) 835-2555. 12% According to a recent Genentech Trends Report, 49% of oncologists report that over the past five years, they are becoming more specialized in terms of treating specific cancer and tumor types. The research also looks at metrics of clinical development productivity and the progress being made to improve representativeness of race Perspectives from Managed Care Organizations, Specialty Pharmacies, Oncologists, Practice Managers, and Employers This content is only available to members. In part two of OBR’s Total Cost of Care series, we examine two key drivers of costs: the shift in the site-of-care for patients and incentives provided in the 340B drug discount program. Their Fight. Across oncology biosimilars, WAC prices discounted between 10-40% compared to reference products. 96 billion by 2030, at a CAGR of 8. 3 million by 2035. dyugwf, soc3a, omcc, pu15, tojj4y, vaui, lyvc1, vqqy, tbf6, 7ytuf,